European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Aktaa, Suleman; Tzeis, Stylianos; Gale, Chris P; Ackerman, Michael J.; Arbelo, Elena; Behr, Elijah; Crotti, Lia; Reddy, Vivek Y.; Churet, Christian De Chillou de; Denekel, Thomas; Figueiredo, Márcio Jansen de Oliveira; Friede, Tim; Leclercq, Christophe; Merino, José Luís; Semsarian, C.; Verstrael, Axel; Zeppenfeld, Katja; Tfelt‐Hansen, Jacob; Reichlin, Tobias

doi:10.1093/europace/euac114

Cited by 20 publications

(13 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The next steps, however, are critical. Ensuring greater access to genetic testing already mandated in guidelines 15 , 136 and consensus statements 5 requires implementation in patient pathways not only in Europe but globally. Only then will access be possible for patients to personalized medical interventions and ultimately therapies tailored to genetic aetiology.…”

Section: Discussionmentioning

confidence: 99%

From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies

Crotti,

Brugada,

Calkins

et al. 2023

Europace

Self Cite

View full text Add to dashboard Cite

In the early nineties, few years before the birth of Europace, the clinical and scientific world of familial arrhythmogenic conditions was revolutionized by the identification of the first disease-causing genes. The explosion of genetic studies over a 15-year period led to the discovery of major disease-causing genes in practically all channelopathies and cardiomyopathies, bringing insight into the pathophysiological mechanisms of these conditions. The birth of next generation sequencing allowed a further step forward and other significant genes, as CALM1–3 in channelopathies and FLN C and TTN in cardiomyopathies were identified. Genotype–phenotype studies allowed the implementation of the genetic results in diagnosis, risk stratification, and therapeutic management with a different level of evidence in different arrhythmogenic conditions. The influence of common genetic variants, i.e. SNPs, on disease manifestation was proved in mid-twenties, and in the last 10 years with the advent of genome-wide association studies performed in familial arrhythmogenic diseases, the concept of polygenic risk score has been consolidated. Now, we are at the start of another amazing phase, i.e. the initiation of first gene therapy clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies

Crotti,

Brugada,

Calkins

et al. 2023

Europace

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the diagnosis and treatment of CVD will continue to represent enormous clinical unmet needs, such therapies as cardiac imaging, cardiac genetics, and CIEDs have played an integral role in handling and improving those diseases (Aktaa et al, 2023). CIEDs have been a…”

Section: Backgrounds For Rm Of Ciedsmentioning

confidence: 99%

Telehealth of cardiac devices for CVD treatment

Shelke,

Veerubhotla,

Lee

et al. 2023

Biotech & Bioengineering

View full text Add to dashboard Cite

This review covers currently available cardiac implantable electronic devices (CIEDs) as well as updated progress in real‐time monitoring techniques for CIEDs. A variety of implantable and wearable devices that can diagnose and monitor patients with cardiovascular diseases are summarized, and various working mechanisms and principles of monitoring techniques for Telehealth and mHealth are discussed. In addition, future research directions are presented based on the rapidly evolving research landscape including Artificial Intelligence (AI).

show abstract

“…The ESC guidelines clearly state that patients’ involvement in the decision-making process and information about specific implications for life with an ICD is a matter of great importance. 1 , 6 In a previous report, we identified major gaps regarding patients’ knowledge and empowerment in this process. 7 Most of the research on European regional differences in ICD therapy focused on implantation rates and predictors of ICD underutilization.…”

Section: Introductionmentioning

confidence: 96%

Regional disparity on patient characteristics and perceptions after implantable cardioverter-defibrillator implantation: results from an EHRA patient survey

et al. 2023

View full text Add to dashboard Cite

Aims The aim of this study was to identify potential regional disparities in characteristics of implantable cardioverter-defibrillator (ICD) recipients, patient perceptions and perspectives after implantation and level of information provided to patients. Methods and results The prospective, multicentre, and multinational European Heart Rhythm Association patient Survey ‘Living with an ICD’ included patients already implanted with an ICD (median ICD dwell time – 5 years, interquartile range 2–10). An online questionnaire was filled-in by patients invited from 10 European countries. A total of 1809 patients (the majority in their 40s to 70s, 65.5% men) were enrolled, with 877 (48.5%) from Western Europe (group 1), followed by 563 from Central/Eastern Europe (group 2, 31.1%), and 369 from Southern Europe (group 3, 20.4%). A total of 52.9% of Central/Eastern Europe patients reported increased satisfaction after ICD placement compared with 46.6% from Western and 33.1% from Southern Europe (1 vs. 2 P = 0.047, 1 vs. 3 P < 0.001, 2 vs. 3 P < 0.001). About 79.2% of Central/Eastern and 76.0% of Southern Europe patients felt optimally informed at the time of device implantation compared with just 64.6% from Western Europe (1 vs. 2 P < 0.001, 1 vs. 3 P < 0.001, 2 vs. 3 P = ns). Conclusions While physicians in Southern Europe should address the patients’ concerns about the impact of the ICD on quality of life, physicians from Western Europe should focus on improving the quality of information provided to their prospective ICD patients. Novel strategies to address regional differences in patients’ quality of life and provision of information are warranted.

show abstract

European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Cited by 20 publications

References 74 publications

From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies

From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies

Telehealth of cardiac devices for CVD treatment

Regional disparity on patient characteristics and perceptions after implantable cardioverter-defibrillator implantation: results from an EHRA patient survey

Contact Info

Product

Resources

About